简介：
Overview
This article presents a human peripheral blood mononuclear cell (PBMC) based humanized xenograft mouse model for immuno-oncology research. The protocol outlines procedures for establishing and characterizing these models to assess immuno-oncology therapies.
Key Study Components
Area of Science
- Immuno-oncology
- Xenograft models
- Translational research
Background
- Human PBMCs can partially reconstitute human immunity in mice.
- Xenograft models are essential for studying human tumors in vivo.
- Cost-effective methods are needed for reproducible research.
- Characterization of immune responses in tumor-bearing mice is crucial.
Purpose of Study
- To provide a guideline for establishing humanized mouse models.
- To facilitate research in immuno-oncology therapies.
- To enhance understanding of human immune responses to tumors.
Methods Used
- Reconstitution of NOD/SCID mice with human PBMCs and tumor cells.
- Administration of cyclophosphamide and disulfiram for myeloid cell depletion.
- Subcutaneous injection of PBMCs and tumor cells into mice.
- Monitoring of tumor volume bi-weekly for four to six weeks.
Main Results
- The protocol allows for effective reconstitution of human immunity.
- Demonstrated reproducibility in tumor growth measurements.
- Provided a framework for future immuno-oncology studies.
- Highlighted the importance of human PBMCs in xenograft models.
Conclusions
- This model can advance the field of immuno-oncology research.
- Establishing humanized models is vital for therapy assessment.
- Further studies can build on this protocol for enhanced insights.
What is a humanized xenograft mouse model?
It is a mouse model reconstituted with human immune cells and tumors to study human immune responses.
Why are PBMCs used in this study?
PBMCs help to partially reconstitute human immunity in the mouse model, making it relevant for human cancer research.
What are the key steps in the protocol?
Key steps include myeloid cell depletion, PBMC and tumor cell injection, and monitoring tumor growth.
How often should tumor volume be measured?
Tumor volume should be measured bi-weekly for four to six weeks.
What is the significance of this research?
It provides a reproducible model for assessing immuno-oncology therapies, which is crucial for translational research.
繁體中文
